Catalent Pharma Solutions has completed the first phase of a $7.3 million investment to upgrade and expand its packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy.
 
The first phase, completed in August 2018, expanded and upgraded the facility’s integrated packaging capabilities, and commissioned the first of five new softgel encapsulation lines. The second phase to add a further four encapsulation lines, will bring the total number of lines to 23 and significantly expand production, drying, and inspection capacity for nutritional supplements and beauty softgels at the site. These four new lines are expected to be fully operational by January 2019.
 
“We have a long and proud history in softgel product development and commercial manufacturing,” commented Dr. Aris Gennadios, president of Catalent Softgel Technologies. “This investment is driven by increasing demand for nutritional and beauty products globally, and will enable Catalent to better serve these markets.”